97 related articles for article (PubMed ID: 2918466)
1. Toxicity of the HMG-coenzyme A reductase inhibitor, lovastatin, to rabbits.
Kornbrust DJ; MacDonald JS; Peter CP; Duchai DM; Stubbs RJ; Germershausen JI; Alberts AW
J Pharmacol Exp Ther; 1989 Feb; 248(2):498-505. PubMed ID: 2918466
[TBL] [Abstract][Full Text] [Related]
2. Biochemical changes and morphological alterations of liver and kidney in hamsters after administration of the HMG-coenzyme A reductase inhibitor, simvastatin: prevention and reversibility by mevalonate.
Oms P; Assie N; Bruniquel F; Degryse AD; van Haverbeke G; Delhon A
Pharmacol Toxicol; 1995 Dec; 77(6):391-6. PubMed ID: 8835365
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro.
Flint OP; Masters BA; Gregg RE; Durham SK
Toxicol Appl Pharmacol; 1997 Jul; 145(1):91-8. PubMed ID: 9221828
[TBL] [Abstract][Full Text] [Related]
4. HMG CoA reductase inhibitor-induced myotoxicity: pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular-weight proteins in neonatal rat muscle cell culture.
Flint OP; Masters BA; Gregg RE; Durham SK
Toxicol Appl Pharmacol; 1997 Jul; 145(1):99-110. PubMed ID: 9221829
[TBL] [Abstract][Full Text] [Related]
5. Tocotrienols potentiate lovastatin-mediated growth suppression in vitro and in vivo.
McAnally JA; Gupta J; Sodhani S; Bravo L; Mo H
Exp Biol Med (Maywood); 2007 Apr; 232(4):523-31. PubMed ID: 17392488
[TBL] [Abstract][Full Text] [Related]
6. RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductase.
Amin D; Rutledge RZ; Needle SN; Galczenski HF; Neuenschwander K; Scotese AC; Maguire MP; Bush RC; Hele DJ; Bilder GE; Perrone MH
J Pharmacol Exp Ther; 1997 May; 281(2):746-52. PubMed ID: 9152381
[TBL] [Abstract][Full Text] [Related]
7. Regulation of early cholesterol biosynthesis in rat liver: effects of sterols, bile acids, lovastatin, and BM 15.766 on 3-hydroxy-3-methylglutaryl coenzyme A synthase and acetoacetyl coenzyme A thiolase activities.
Honda A; Salen G; Nguyen LB; Xu G; Tint GS; Batta AK; Shefer S
Hepatology; 1998 Jan; 27(1):154-9. PubMed ID: 9425931
[TBL] [Abstract][Full Text] [Related]
8. Lovastatin-induced proliferation inhibition and apoptosis in C6 glial cells.
Choi JW; Jung SE
J Pharmacol Exp Ther; 1999 Apr; 289(1):572-9. PubMed ID: 10087052
[TBL] [Abstract][Full Text] [Related]
9. Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia.
Pappu AS; Bacon SP; Illingworth DR
J Lab Clin Med; 2003 Apr; 141(4):250-6. PubMed ID: 12677170
[TBL] [Abstract][Full Text] [Related]
10. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
11. Mevalonate supplementation in pregnant rats suppresses the teratogenicity of mevinolinic acid, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme a reductase.
Minsker DH; MacDonald JS; Robertson RT; Bokelman DL
Teratology; 1983 Dec; 28(3):449-56. PubMed ID: 6665743
[TBL] [Abstract][Full Text] [Related]
12. Requirement for mevalonate in cycling cells: quantitative and temporal aspects.
Doyle JW; Kandutsch AA
J Cell Physiol; 1988 Oct; 137(1):133-40. PubMed ID: 3170653
[TBL] [Abstract][Full Text] [Related]
13. Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications.
Dimitroulakos J; Ye LY; Benzaquen M; Moore MJ; Kamel-Reid S; Freedman MH; Yeger H; Penn LZ
Clin Cancer Res; 2001 Jan; 7(1):158-67. PubMed ID: 11205904
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer.
Thibault A; Samid D; Tompkins AC; Figg WD; Cooper MR; Hohl RJ; Trepel J; Liang B; Patronas N; Venzon DJ; Reed E; Myers CE
Clin Cancer Res; 1996 Mar; 2(3):483-91. PubMed ID: 9816194
[TBL] [Abstract][Full Text] [Related]
15. Regulation of proliferation and Ras localization in transformed cells by products of mevalonate metabolism.
Cuthbert JA; Lipsky PE
Cancer Res; 1997 Aug; 57(16):3498-505. PubMed ID: 9270019
[TBL] [Abstract][Full Text] [Related]
16. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs.
Davis HR; Pula KK; Alton KB; Burrier RE; Watkins RW
Metabolism; 2001 Oct; 50(10):1234-41. PubMed ID: 11586500
[TBL] [Abstract][Full Text] [Related]
17. Biochemical changes and morphological alterations of the liver in guinea-pigs after administration of simvastatin (HMG CoA reductase-inhibitor).
Horsmans Y; Desager JP; Harvengt C
Pharmacol Toxicol; 1990 Oct; 67(4):336-9. PubMed ID: 2077527
[TBL] [Abstract][Full Text] [Related]
18. Role of cholesterol-enriched diet and the mevalonate pathway in cardiac nitric oxide synthesis.
Giricz Z; Csonka C; Onody A; Csont T; Ferdinandy P
Basic Res Cardiol; 2003 Sep; 98(5):304-10. PubMed ID: 12955403
[TBL] [Abstract][Full Text] [Related]
19. Mevalonate reverses the developmental arrest of preimplantation mouse embryos by Compactin, an inhibitor of HMG Co A reductase.
Surani MA; Kimber SJ; Osborn JC
J Embryol Exp Morphol; 1983 Jun; 75():205-23. PubMed ID: 6886611
[TBL] [Abstract][Full Text] [Related]
20. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors unmask cryptic regulatory mechanisms.
Lopez D; Chambers CM; Ness GC
Arch Biochem Biophys; 1997 Jul; 343(1):118-22. PubMed ID: 9210653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
